“…PRIMA-1 (p53 reactivation and induction of massive apoptosis 1 or APR-246), a widely used investigational drug for cancer therapy successfully tested in phase I/II clinical trials [1,2,3], triggers apoptosis of tumor cells and augments the tumor cell apoptosis following cytostatic treatment, radiation or hypoxia [1,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29]. The substance is at least partially effective by reactivating the proapoptotic transcription factor p53 [1,3,4,5,7,8,11,12,13,14,16,18,19,20,21,23,25,26,27,30].…”